• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

    26.74 +2.48 (+10.22%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Assembly Biosciences, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead ↗
    Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming... 
    Via MarketBeat
    News headline image
    Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands ↗
    Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease... 
    Via MarketBeat
    News headline image
    Assembly Biosciences Announces Upcoming Investor Conference Presentations
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗
    Via Stocktwits
    News headline image
    Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗
    Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing... 
    Via MarketBeat
    News headline image
    Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with Strong Growth Fundamentals ↗
    Assembly Biosciences (ASMB) exemplifies a high-growth momentum stock, meeting strict technical uptrend criteria and showing accelerating earnings and sales fundamentals. 
    Via Chartmill
    News headline image
    Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with High Growth Momentum ↗
    Assembly Biosciences (ASMB) stock meets Mark Minervini's Trend Template with a perfect technical rating, 397% from lows, and accelerating 298% revenue growth. 
    Via Chartmill
    News headline image
    Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Forecasting The Future: 4 Analyst Projections For Assembly Biosciences ↗
     
    Via Benzinga
    News headline image
    Assembly Biosciences Announces Upcoming Investor Conference Participation
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
    Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.